In vivo tracking for cell therapies

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 49, Issue 4, 2005, Pages 339-348

  Thompson, M ^a   Wall, Dominic M ^a   Hicks, R J ^a,b   Prince, H M ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cell therapy; Emission computed; Radiopharmceuticals; Tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; INDIUM 111; RADIOISOTOPE;

BODY DISTRIBUTION; CELL LABELING; CELL MIGRATION; CELL TRANSPLANTATION; CLINICAL TRIAL; DENDRITIC CELL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MACROPHAGE; MONOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; REVIEW; SCINTISCANNING; SENSITIVITY ANALYSIS; THREE DIMENSIONAL IMAGING;

ANIMALS; CELL TRANSPLANTATION; HUMANS; MONOCYTES; RADIOISOTOPES; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 32644469285     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
2. Jefford M, Maraskovsky E, Cebon J, Davis ID. The use of dendritic cells in cancer therapy. Lancet Oncol 2001;2:343-53.
3. Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59:3340-5.
4. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 2003;17:545-80.
5. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999;11:753-61.
6. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000;1:510-4.
7. Lopez M, Fechtenbaum J, David B, Martinache C, Chokri M, Canepa S et al. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study. J Immunother 1992;11:209-17.
8. Faradji A, Bohbot A, Frost H, Schmitt-Goguel M, Siffert JC, Dufour P et al. Phase I study of liposomal MTP-PE-activated autologous monocytes administered intraperitoneally to patients with peritoneal carcinomatosis. J Clin Oncol 1991;9:1251-60.
9. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995;13:2281-92.
10. Gosselin EJ, Wardwell K, Gosselin DR, Alter N, Fisher JL, Guyre PM. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J Immunol 1992; 149:3477-81.
11. Osman S, Danpure HJ. The use of 2-(18F)fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B 1992;19:183-90.
12. Forstrom LA, Dunn WL, Mullan BP, Hung JC, Lowe VJ, Thorson LM. Biodistribution and dosimetry of [(18)F]fluorodeoxyglucose labelled leukocytes in normal human subjects. Nucl Med Commun 2002; 23:721-5.
13. Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999;93:1287-98.
14. Apostolopoulos V, McKenzie IF, Pietersz GA. Breast cancer immunotherapy: current status and future prospects. Immunol Cell Biol 1996;74:457-64.
15. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001;166:4254-9.
16. Kukutsch NA, Rossner S, Austyn JM, Schuler G, Lutz MB. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J Invest Dermatol 2000;115:449-53.
17. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 1999;93:2411-9.
18. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999;83:215-22.
19. Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000;108:805-16.
20. Paik JY, Lee KH, Byun SS, Choe YS, Kim BT. Use of insulin to improve [18 F]fluorodeoxyglucose labelling and retention for in vivo positron emission tomography imaging of monocyte trafficking. Nucl Med Commun 2002:23:551-7.
21. Deichen JT, Prante O, Gack M, Schmiedehausen K, Kuwert T. Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med Mol Imaging 2003;30: 267-73.
22. Melder RJ, Elmaleh D, Brownell AL, Brownell GL, Jain RK. A method for labeling cells for positron emission tomography (PET) studies. J Immunol Methods 1994;175:79-87.
23. Jones HA, Peters AM, Clark JC. 18F-FDG labelling of human leukocytes. Nucl Med Commun 2001;22:601-2.
24. Quillien V, Moisan A, Lesimple T, Leberre C, Toujas L. Biodistribution of 111indium-labeled macrophages infused intravenously in patients with renal carcinoma. Cancer Immunol Immunother 2001;50:477-82.
25. Manienhagen J, Hennemann B, Andreesen R, Eilles C. 111In-oxine labelling of tumour-cytotoxic macrophages generated in vitro from circulating blood monocytes: an in vitro evaluation. Nucl Med Commun 1995;16:357-61.
26. Faradji A, Bohbot A, Schmitt-Goguel M, Roeslin N, Dumont S, Wiesel ML et al. Phase I trial of intravenous infusion of ex-vivo-activated autologous blood-derived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immunother 1991;33:319-26.
27. Mackensen A, Krause T, Blum U, Uhrmeister P, Mertelsmann R, Lindemann A. Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 1999;48:118-22.
28. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12-7.
29. Quillien V, Moisan A, Carsin A, Lesimple T, Lefeuvre C, Adamski H et al. Biodistribution of radiolabelled human dendritic cells injected by various routes. Eur J Nucl Med Mol Imaging 2005;32: 731-41.
30. Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004;2:27.
31. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56-8.
32. Blocklet D, Toungouz M, Kiss R, Lambermont M, Velu T, Duriau D et al. 111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Mol Imaging 2003;30:440-7.
33. Hildebrandt IJ, Gambhir SS. Molecular imaging applications for immunology. Clin Immunol 2004;111:210-24.
34. Allport JR, Weissleder R. In vivo imaging of gene and cell therapies. Exp Hematol 2001;29:1237-46.
35. Daldrup-Link HE, Rudelius M, Oostendorp RA, Settles M, Piontek G, Metz S et al. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology 2003;228:760-7.
36. Bulte JW, Duncan ID, Frank JA. In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J Cereb Blood Flow Metab 2002;22:899-907.
37. Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004;39:56-63.
38. Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001;19:1141-7.
39. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation 2003;76: 1123-30.
40. Ahrens ET, Feili-Hariri M, Xu H, Genove G, Morel PA. Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn Reson Med 2003;49:1006-13.
41. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000;18:410-4.
42. Daldrup-Link HE, Rudelius M, Metz S, Piontek G, Pichler B, Settles M et al. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur J Nucl Med Mol Imaging 2004;31:1312-21.
43. Arbab AS, Yocum GT, Kalish H, Jordan EK, Anderson SA, Khakoo AY et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004;104:1217-23.
44. Olasz EB, Lang L, Seidel J, Green MV, Eckelman WC, Katz SI. Fluorine-18 labeled mouse bone marrow-derived dendritic cells can be detected in vivo by high resolution projection imaging. J Immunol Methods 2002;260:137-48.
45. Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, Phelps ME et al. Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci U S A 2002;99:3030-5.
46. Viehl CT, Becker-Hapak M, Lewis JS, Tanaka Y, Liyanage UK, Linehan DC et al. A tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol 2005;12:517-25.
47. Korf J, Veenma-van der Duin L, Brinkman-Medema R, Niemarkt A, de Leij LF. Divalent cobalt as a label to study lymphocyte distribution using PET and SPECT. J Nucl Med 1998;39:836-41.
48. Gundersen HJ, Hansen SB, Gjedde A, Stodkilde-Jorgensen H, Marqversen J, Agger R et al. A methodology for quantifying and visualising cell homing/accumulation by combined positron emission tomography and magnetic resonance imaging. Proceedings of SPIE 2004;5369:361-70.
49. Matsui K, Wang Z, McCarthy TJ, Allen PM, Reichert DE. Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET. Nucl Med Biol 2004;31:1021-31.
50. Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol 2003;21:405-13.
51. Dubey P, Su H, Adonai N, Du S, Rosato A, Braun J et al. Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci U S A 2003;100:1232-7.
52. Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002:43:1188-200.